Certara (NASDAQ:CERT) Releases FY24 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.41 to $0.46 for the period, compared to the consensus estimate of $0.44. The company issued revenue guidance of $385 million to $400 million, compared to the consensus revenue estimate of $391.38 million.

Analyst Ratings Changes

Several research firms recently commented on CERT. JMP Securities restated a market perform rating on shares of Certara in a report on Wednesday, July 10th. KeyCorp decreased their price target on shares of Certara from $23.00 to $20.00 and set an overweight rating for the company in a report on Thursday, July 11th. UBS Group cut their price objective on shares of Certara from $20.00 to $16.00 and set a neutral rating on the stock in a research report on Wednesday. Robert W. Baird cut their price objective on shares of Certara from $19.00 to $18.00 and set a neutral rating on the stock in a research report on Wednesday. Finally, Barclays dropped their price target on shares of Certara from $18.00 to $16.00 and set an equal weight rating on the stock in a research report on Friday, June 28th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $18.83.

Certara Trading Down 13.6 %

Shares of CERT stock traded down $2.05 on Wednesday, reaching $13.03. The company had a trading volume of 1,541,818 shares, compared to its average volume of 573,008. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average of $15.10 and a 200-day moving average of $16.52. Certara has a 12 month low of $11.81 and a 12 month high of $19.87. The stock has a market cap of $2.10 billion, a PE ratio of -33.41, a PEG ratio of 5.39 and a beta of 1.52.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The business had revenue of $96.65 million during the quarter, compared to analyst estimates of $94.48 million. On average, equities analysts forecast that Certara will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.